Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Pharma Ltd.

Division of Vifor Pharma Group
www.viforpharma.com

Latest From Vifor Pharma Ltd.

Next Up For AstraZeneca: Building Out In Renal Disease

US President Ruud Dobber talked to Scrip about expanding in renal disease, balancing the fast-growing oncology portfolio against other priority disease areas, and the company's anticipated return to growth. The big challenge going into 2019, he said, is external factors. "I'm not able to change the view of the President," he said.

Leadership Launches

Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear

First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.


Biosimilars Approvals

Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear

First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.


Biosimilars Approvals

AstraZeneca’s ZS-9 Delay In US Gives Veltassa An Edge

FDA issued a second complete response letter to AstraZeneca’s NDA for ZS-9 for hyperkalaemia, a potential blockbuster that would compete against Vifor Pharma’s Veltassa.

Complete Response Letters Manufacturing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • Søren Tulstrup, PhD, CEO
    Alex Sigalas, CFO
    Stefan Wohlfeil, Head, R&D & CMO
  • Contact Info
  • Vifor Pharma Ltd.
    Phone: (41) 58 851 80 00
    Flughofstrasse 61
    Zurich, GH-8152
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register